Agilent Technologies, a global leader in life sciences, diagnostics and applied chemical markets acquires BioTek, a worldwide leader in the design, manufacture, and distribution of innovative life science instrumentation for $1.165bn. Combined portfolio enables Agilent to provide a more complete and integrated solution for customers in the important and fast-growing area of live cell analysis. The transaction is expected to be completed in Agilent's fiscal fourth quarter of this year, subject to regulatory approvals and customary closing conditions. "BioTek represents a strong strategic fit with Agilent," said Mike McMullen, Agilent president, and CEO. "The combination of these two companies will accelerate our multi-year growth strategy to expand our position in cell analysis.